HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Checking Boxes Toward Consumer Health Spinoff, J&J Notes Costs For Preparing To Change

Executive Summary

Firm adds outside-the-box details about planned spinoff with its third quarter results on 18 October, which included worldwide consumer results slipping 0.4% to $3.8bn on a 2.1% increase in the offset by 2.3% international decline.

You may also be interested in...

J&J Limited On Offering Consumer Business Separation Details, Clear On Q4 Revenue Drag

“We made significant progress towards the separation of Kenvue,” says CEO Jaoquin Duoto. But fourth-quarter and full-year progress on consumer sales growth was impeded by loss to foreign currency exchange.

US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?

Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.

Strongest US Cough/Cold Season In 10 Years Likely

Increasing numbers cough/cold drug prescriptions combined with consumers’ waning interest in flu vaccines point to 2022-2023 season rivaling decade-high levels from 2017-18 and to retailers boosting inventories through year-end, Raymond James analysts say.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts